{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T10:45:18Z","timestamp":1779360318273,"version":"3.51.4"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:00:00Z","timestamp":1701993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Anaplastic Large Cell Lymphoma (ALCL) is one of the most common subtypes of T-cell lymphoma. Among these, refractory and relapsed (r\/r) ALK positive ALCL lacks effective therapies. The chimeric antigen receptor-modified T (CAR-T) cell therapy holds great promise as a therapeutic strategy for this disease. However, it is not known yet whether anti-CD5 CAR-T cells are sufficient for the definitive treatment of relapsed ALK<jats:sup>+<\/jats:sup> ALCL, nor the role of accurate laboratory-based diagnoses during CAR-T treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>The adolescent patient received autologous T cells containing sequences encoding V<jats:sub>H<\/jats:sub> domains specific to CD5. Following the infusion, there was an increase in both the copy number and proportion of CAR-T cells in peripheral blood. IL-6 and ferritin levels in the patient exhibited significant fluctuations, with increases of 13 and 70 folds respectively, compared to baseline after the treatment. Additionally, adverse effects were observed, including grade 4 rash, grade 1 headache, nausea, and neck-pain. Surprisingly, a relapsed disease phenotype was identified based on the results of PET\/CT and histopathological analysis of the inguinal lymph node biopsy. After conducting a thorough diagnostic assessment, which included flow cytometry, next-generation sequencing (NGS), examination of immune-related gene rearrangements, and analysis of the immune repertoire of T-cell receptors (TCR), we conclusively determined that the hyperplastic T cells identified in the lymph node were the result of an expansion of CAR-T cells. Ultimately, the patient has attained complete remission (CR) and has sustained a disease-free survival state for 815 days as of the cutoff date on August 30, 2023.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Taken together, the results demonstrate that anti-CD5 CAR-T cells can induce a clinical response in r\/r ALK<jats:sup>+<\/jats:sup> ALCL patient. Furthermore, this case underscores the importance of utilizing advanced technologies with high sensitivity and accuracy for biological detection in clinical laboratory diagnosis and prognosis in CAR-T cell treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration number<\/jats:title><jats:p>NCT04767308.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1280007","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T12:30:42Z","timestamp":1702038642000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Case report: Differential diagnosis of highly amplified anti-CD5 CAR T cells and relapsed lymphoma cells in a patient with refractory ALK positive anaplastic large cell lymphoma"],"prefix":"10.3389","volume":"14","author":[{"given":"Wei","family":"Mu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meilan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunfeng","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caixia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kefeng","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenyu","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojian","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qilin","family":"Ao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,12,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12360","article-title":"Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease","volume":"93","author":"Eyre","year":"2014","journal-title":"Eur J haematology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.12.3681","article-title":"CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features","volume":"96","author":"Stein","year":"2000","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin oncology: Off J Am Soc Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.20.1764","article-title":"Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: a report from the French Society of Pediatric Oncology","volume":"27","author":"Brugi\u00e8res","year":"2009","journal-title":"J Clin oncology: Off J Am Soc Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/jco.18.01457","article-title":"CD19 chimeric antigen receptor therapy for refractory aggressive B-cell lymphoma","volume":"37","author":"Jacobson","year":"2019","journal-title":"J Clin oncology: Off J Am Soc Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-887067","article-title":"The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells","volume":"133","author":"Hirayama","year":"2019","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V82.2.343.343","article-title":"Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia","volume":"82","author":"Pui","year":"1993","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.07.001","article-title":"The rational development of CD5-targeting biepitopic CARs with fully human heavy-chain-only antigen recognition domains","volume":"29","author":"Dai","year":"2021","journal-title":"Mol therapy: J Am Soc Gene Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0285-8","article-title":"CAR T-cells for T-cell Malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells","volume":"32","author":"Alcantara","year":"2018","journal-title":"Leukemia"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.803693","article-title":"A model perspective explanation of the long-term sustainability of a fully human BCMA-targeting CAR (CT103A) T-cell immunotherapy","volume":"13","author":"Mu","year":"2022","journal-title":"Front Pharmacol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.jmoldx.2020.02.007","article-title":"Detection and quantification of chimeric antigen receptor transgene copy number by droplet digital PCR versus real-time PCR","volume":"22","author":"Lou","year":"2020","journal-title":"J Mol diagnostics: JMD"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.16176","article-title":"Ruxolitinib mitigates steroid-refractory CRS during CAR T therapy","volume":"25","author":"Pan","year":"2021","journal-title":"J Cell Mol Med"},{"key":"B13","article-title":"[Overview of lymphoid neoplasms in the fourth edition of the WHO classification]","volume":"60","author":"Tohda","year":"2012","journal-title":"Rinsho byori. Japanese J Clin Pathol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3960\/jslrt.17023","article-title":"Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects","volume":"57","author":"Tsuyama","year":"2017","journal-title":"J Clin Exp hematopathology: JCEH"},{"key":"B15","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1182\/blood-2019-129559","article-title":"Safety and anti-tumor activity of CD5 CAR T-cells in patients with relapsed\/refractory T-cell Malignancies","volume":"134","author":"Hill","year":"2019","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/blood-2021-149999","article-title":"A single-arm, open-label, pilot trial of autologous CD7-CAR-T cells for CD7 positive relapsed and refractory T-lymphoblastic leukemia\/lymphoma","volume":"138","author":"Zhang","year":"2021","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.00389","article-title":"Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human, phase I trial","volume":"39","author":"Pan","year":"2021","journal-title":"J Clin Oncology: Off J Am Soc Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.bbrc.2022.01.070","article-title":"Ruxolitinib reduces severe CRS response by suspending CAR-T cell function instead of damaging CAR-T cells","volume":"595","author":"Xu","year":"2022","journal-title":"Biochem Biophys Res Commun"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.586.586","article-title":"Decreased rates of severe CRS seen with early intervention strategies for CD19 CAR-T cell toxicity management","volume":"128","author":"Gardner","year":"2016","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"New Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/s1470-2045(09)70074-9","article-title":"Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study","volume":"10","author":"Ciceri","year":"2009","journal-title":"Lancet Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41392-022-00898-z","article-title":"T cells expressing CD5\/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape","volume":"7","author":"Dai","year":"2022","journal-title":"Signal transduction targeted Ther"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1280007\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T12:30:44Z","timestamp":1702038644000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1280007\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,8]]},"references-count":22,"alternative-id":["10.3389\/fimmu.2023.1280007"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1280007","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,8]]},"article-number":"1280007"}}